Your browser doesn't support javascript.
loading
Current management of children and young people with heterozygous familial hypercholesterolaemia - HEART UK statement of care.
Ramaswami, Uma; Humphries, Steve E; Priestley-Barnham, Lorraine; Green, Peter; Wald, David S; Capps, Nigel; Anderson, Mark; Dale, Peter; Morris, Andrew A.
Afiliação
  • Ramaswami U; Lysosomal Disorders Unit, Royal Free London NHS Foundation Trust, London, United Kingdom. Electronic address: uma.ramaswami@nhs.net.
  • Humphries SE; Centre for Cardiovascular Genetics, Institute for Cardiovascular Science, University College London, London, United Kingdom.
  • Priestley-Barnham L; Royal Brompton & Harefield NHS Foundation Trust, Harefield Hospital, London, United Kingdom.
  • Green P; High Parks Medical Centre, Parkside, Cliffe Woods, Kent, United Kingdom.
  • Wald DS; Wolfson Institute of Preventative Medicine, Queen Mary University of London, Charterhouse Square, London, United Kingdom.
  • Capps N; Department of Clinical Biochemistry, The Shrewsbury and Telford Hospital NHS Trust, Princess Royal Hospital, Telford, United Kingdom.
  • Anderson M; Great North Children's Hospital, Newcastle, United Kingdom.
  • Dale P; Department of Paediatrics, Royal Gwent Hospital, Newport, Wales, United Kingdom.
  • Morris AA; Willink Metabolic Unit, Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom.
Atherosclerosis ; 290: 1-8, 2019 11.
Article em En | MEDLINE | ID: mdl-31536851
ABSTRACT
This consensus statement on the management of children and young people with heterozygous familial hypercholesterolaemia (FH) addresses management of paediatric FH in the UK, identified by cascade testing when a parent is diagnosed with FH and for those diagnosed following incidental lipid tests. Lifestyle and dietary advice appropriate for children with FH; suggested low density lipoprotein cholesterol (LDL-C) targets and the most appropriate lipid-lowering therapies to achieve these are discussed in this statement of care. Based on the population prevalence of FH as ~1/250 and the UK paediatric population, there are approximately 50,000 FH children under 18 years. Currently only about 550 of these children and young people have been identified and are under paediatric care.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Hidroximetilglutaril-CoA Redutases / Comportamento de Redução do Risco / Dieta Saudável / Heterozigoto / Hiperlipoproteinemia Tipo II Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Child / Humans País/Região como assunto: Europa Idioma: En Revista: Atherosclerosis Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Hidroximetilglutaril-CoA Redutases / Comportamento de Redução do Risco / Dieta Saudável / Heterozigoto / Hiperlipoproteinemia Tipo II Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Child / Humans País/Região como assunto: Europa Idioma: En Revista: Atherosclerosis Ano de publicação: 2019 Tipo de documento: Article